Summarized by Masters of Longevity from Longevity Technology.
An article previewing a biotech partnership using AI-driven protein design to pursue multispecific therapeutics for metabolic and obesity-related diseases, outlining the collaboration’s scope and strategic roles.
Key Takeaways
- Generate Biomedicines will lead AI-enabled discovery and nominate lead candidates for two initial multispecific protein programs targeting metabolic disease.
- Zealand Pharma will assume clinical development, regulatory submissions, and global commercialization for candidates selected from the collaboration.
- Generate received $30 million upfront plus up to $35 million in early preclinical payments and is eligible for nearly $1.2 billion in total milestones with tiered royalties.
